BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 32763779)

  • 1. Cognitive dysfunction in patients with nasopharyngeal carcinoma after induction chemotherapy.
    Wang J; Lian CL; Zheng H; Lin LE; Yu YF; Lin Q; Wu SG
    Oral Oncol; 2020 Dec; 111():104921. PubMed ID: 32763779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction chemotherapy plus IMRT alone versus induction chemotherapy plus IMRT-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study.
    Wei Z; Zhang Z; Luo J; Li N; Peng X
    J Cancer Res Clin Oncol; 2019 Jul; 145(7):1857-1864. PubMed ID: 31062162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients based on induction chemotherapy response.
    Liu SL; Sun XS; Yan JJ; Chen QY; Lin HX; Wen YF; Guo SS; Liu LT; Xie HJ; Tang QN; Liang YJ; Li XY; Lin C; Du YY; Yang ZC; Xiao BB; Yang JH; Tang LQ; Guo L; Mai HQ
    Radiother Oncol; 2019 Aug; 137():83-94. PubMed ID: 31078941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy of induction chemotherapy in the treatment of stage II nasopharyngeal carcinoma in intensity modulated radiotherapy era.
    Li PJ; Mo HY; Luo DH; Hu WH; Jin T
    Oral Oncol; 2018 Oct; 85():95-100. PubMed ID: 30220326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Temporal Cerebral Microbleeds Are Associated With Radiation Necrosis and Cognitive Dysfunction in Patients Treated for Nasopharyngeal Carcinoma.
    Shen Q; Lin F; Rong X; Yang W; Li Y; Cai Z; Xu P; Xu Y; Tang Y
    Int J Radiat Oncol Biol Phys; 2016 Apr; 94(5):1113-20. PubMed ID: 27026315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Xerostomia: An easily ignored symptom induced by induction chemotherapy in patients with nasopharyngeal carcinoma.
    Zhou P; Zhou R; Yu YF; Rao MY; Wu SG
    Head Neck; 2023 Dec; 45(12):3024-3032. PubMed ID: 37750446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients based on plasma Epstein-Barr virus DNA level after induction chemotherapy.
    Liu SL; Sun XS; Liu LT; Sun R; Luo DH; Chen QY; Lin HX; Yuan L; Tang LQ; Guo L; Mai HQ
    Aging (Albany NY); 2020 Mar; 12(6):4931-4944. PubMed ID: 32221045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing the induction chemotherapy regimen for patients with locoregionally advanced nasopharyngeal Carcinoma: A big-data intelligence platform-based analysis.
    Peng H; Tang LL; Chen BB; Chen L; Li WF; Mao YP; Liu X; Zhang Y; Liu LZ; Tian L; Guo Y; Sun Y; Ma J
    Oral Oncol; 2018 Apr; 79():40-46. PubMed ID: 29598949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matched analysis of induction chemotherapy plus chemoradiotherapy versus induction chemotherapy plus radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a multicenter study.
    Zhang B; Hu Y; Xiong RH; Pan YF; Xu QL; Kong XY; Cai R; Chen QQ; Tang HY; Jiang W
    Oncotarget; 2017 Feb; 8(8):14078-14088. PubMed ID: 27845907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction Chemotherapy Followed by Radiotherapy versus Concurrent Chemoradiotherapy in elderly patients with nasopharyngeal carcinoma: finding from a propensity-matched analysis.
    Zeng Q; Wang J; Lv X; Li J; Yin LJ; Xiang YQ; Guo X
    BMC Cancer; 2016 Aug; 16(1):693. PubMed ID: 27577729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment outcomes after reduction of the target volume of intensity-modulated radiotherapy following induction chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: A prospective, multi-center, randomized clinical trial.
    Yang H; Chen X; Lin S; Rong J; Yang M; Wen Q; Shang C; He L; Ren P; Xu S; Zhang J; Liu Q; Pang H; Shi X; Fan J; Sun X; Ma D; Tan B; Zhang T; Zhang L; Hu D; Du X; Zhang Y; Wen S; Zhang X; Wu J
    Radiother Oncol; 2018 Jan; 126(1):37-42. PubMed ID: 28864073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-epidermal growth factor receptor therapy concurrently with induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma.
    Peng H; Tang LL; Liu X; Chen L; Li WF; Mao YP; Zhang Y; Liu LZ; Tian L; Guo Y; Sun Y; Ma J
    Cancer Sci; 2018 May; 109(5):1609-1616. PubMed ID: 29575438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of induction chemotherapy with cisplatin, fluorouracil, with or without taxane on locoregionally advanced nasopharyngeal carcinoma: a retrospective, propensity score-matched analysis.
    Liu GY; Lv X; Wu YS; Mao MJ; Ye YF; Yu YH; Liang H; Yang J; Ke LR; Qiu WZ; Huang XJ; Li WZ; Guo X; Xiang YQ; Xia WX
    Cancer Commun (Lond); 2018 May; 38(1):21. PubMed ID: 29764487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic value of volumetric reduction of the target lesions after induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma.
    Xiang ZZ; Liu F; Yan RN; Zeng YY; He T; Zeng Z; Zhu ZH; Bai L; Ma JC; Liu L
    Head Neck; 2019 Jun; 41(6):1863-1872. PubMed ID: 30620441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival without concurrent chemotherapy for locoregionally advanced nasopharyngeal carcinoma treated with induction chemotherapy plus intensity-modulated radiotherapy: Single-center experience from an endemic area.
    Fangzheng W; Chuner J; Haiyan Q; Quanquan S; Zhimin Y; Tongxin L; Jiping L; Peng W; Kaiyuan S; Zhenfu F; Yangming J
    Medicine (Baltimore); 2019 Dec; 98(51):e18484. PubMed ID: 31861031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The comparison of prognostic value of tumour volumetric regression ratio and RECIST 1.1 criteria after induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma.
    Zeng YY; Xiang ZZ; He T; Liu F; Shao BF; Yan RN; Ma JC; Wang XR; Liu L
    Oral Oncol; 2020 Dec; 111():104924. PubMed ID: 32736209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concurrent chemoradiotherapy with/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Long-term results of phase 3 randomized controlled trial.
    Li WF; Chen NY; Zhang N; Hu GQ; Xie FY; Sun Y; Chen XZ; Li JG; Zhu XD; Hu CS; Xu XY; Chen YY; Hu WH; Guo L; Mo HY; Chen L; Mao YP; Sun R; Ai P; Liang SB; Long GX; Zheng BM; Feng XL; Gong XC; Li L; Shen CY; Xu JY; Guo Y; Chen YM; Zhang F; Lin L; Tang LL; Liu MZ; Ma J; Sun Y
    Int J Cancer; 2019 Jul; 145(1):295-305. PubMed ID: 30613964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sleep in nasopharyngeal carcinoma patients before chemotherapy, after induction chemotherapy, and after concurrent chemoradiotherapy.
    Mo Y; Zhu X; Lai X; Li L
    Med Hypotheses; 2020 Nov; 144():109840. PubMed ID: 32505065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical efficacy of alternating chemo-radiotherapy for locally advanced nasopharyngeal carcinoma].
    You X; Yang Y
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2014 Mar; 28(6):376-80. PubMed ID: 24961123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of early intervention training on cognitive impairment in critical patients].
    Zhao J; Yao L; Li M; Ji X; Zhu X
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2019 Mar; 31(3):298-302. PubMed ID: 30914089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.